期刊文献+

行为疗法联合托特罗定治疗女性膀胱过度活动症伴急迫性尿失禁的疗效观察 被引量:3

Observation on effect of behavioral therapy combined with tolterodine in treating female overactive bladder complicating urge urinary incontinence
下载PDF
导出
摘要 目的探讨行为疗法联合托特罗定治疗女性膀胱过度活动症(OAB)伴急迫性尿失禁(UUI)的临床疗效。方法选取北京市清河社区卫生服务中心就诊的女性OAB伴UUI患者91例,按就诊时间随机分为2组,A组45例,给予口服托特罗定8周;B组46例,给予行为疗法联合口服托特罗定联合治疗8周。比较2组治疗后患者的排尿日记、生活质量评分和尿流动力学检查结果。结果治疗后2组患者24h排尿次数、24h尿失禁次数均明显减少,每次排尿量、膀胱测压容积均明显增加,生活质量评分均改善,B组较A组效果更明显,差异有统计学意义(P<0.05)。结论行为疗法联合托特罗定比单用托特罗定治疗女性OAB伴UUI更有效。 Objective To investigate the clinical effect of the behavioral therapy combined with tolterodine in treating female overactive bladder(OAB) complicating UUI .Methods 91 cases of female pateints with OAB compli‐cating UUI in our center were randomly divided into the two groups according to the visiting time sequence .The group A(45 cases) was treated by oral tolterodine and the group B(46 cases) was treated by the behavioral therapy combined with tolterodine for 8 weeks .The urination daily record ,scores of life quality and urodynamic detection re‐sults after treatment were compared between the two groups .Results The mean 24 h urination frequency and 24 h incontinence frequency after treatment in the two groups were significantly decreased ,each urination volume and bladder pressure volume were significantly increased ,and the life quality was improved ,but the effects in the group B were more significantly than those in the group A ,the differences were statistically significant(P〈 0 .05) .Conclusion The behavioral therapy combined with tolterodine is more effective in treating female OAB and UUI than singletolterodine .
作者 汪美红
出处 《检验医学与临床》 CAS 2015年第15期2214-2215,共2页 Laboratory Medicine and Clinic
关键词 膀胱过度活动 急迫性尿失禁 行为疗法 托特罗定 疗效 overactive bladder urge urinary incontinence behavioral therapy tolterodine therapeutic effects
  • 相关文献

参考文献12

  • 1Stewart WF, Rooyen JB, Cundiff GW,et al. Prevalenceand burden of overactive bladder in the United States[J],World J Urol,2003,20(6) :327-336.
  • 2金锡御.急迫性尿失禁[J].中华泌尿外科杂志,2002,23(5):319-320. 被引量:23
  • 3Norton PA, Zinner NR, Yalcin I, et al. Duloxetine versusplacebo in the treatment of stress urinary incontinence[J]. Am J Obstet Gynecol,2002,187(1) :40-48.
  • 4Hashim H,Abrams P. Drug treatment of overactive blad-i f-der: efficacy, cost and quality-of-life considerations [J].Drugs,2004,64(15) :1643-16.56.
  • 5吴士良,杨勇,薛兆英,那彦群,宋波,金锡御,丁强,张元芳,郭应禄.新型抗胆碱能药物托特罗定治疗膀胱过度活动症的临床研究[J].中华泌尿外科杂志,2001,22(4):217-219. 被引量:91
  • 6袁宁.治疗膀胱过度活动症的新药托特罗定[J].药学进展,2001,25(1):52-56. 被引量:15
  • 7Crandall C. Combination treatment of osteoporosis : a clin-ical review[J], J Womens Health Gend Based Med,2002 ,11(3):211-224..
  • 8Malone-Lee J,Shaffu B,Anand C,et al. Tolterodine:supe-"'.. ..irior tolerability than and comparable efficacy to oxy.buty-nin in individuals 50 years old or older with overactivebladder: a randomized controlled trial [J], J Urol, 2001,165(5):1452-1456.
  • 9Boyington AR. Pelvic muscle exercise effect on pelvicmuscle performance in women [J]. Int Urogynecol J,2000,11(4) :212-218.
  • 10Delorme E. Transobturator urethral suspension: mini-in-vasive procedure in the treatment of stress urinary incon-tinence in women[J]. Progres En Urologie,2002,11(6):1306-1313.

二级参考文献21

  • 1[1]Yarker YE, Goa KG, Fittin A. Oxybutynin, a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in detrusor instability [J]. Drug Aging, 1995, 6(3): 243-262.
  • 2[2]Nilvebrant L, Sundquist S, Gillberg P-G. Tolterodine is not subtype (ml - m5 ) selective but exhibits functional bladder selectivity in vivo [J]. Neurourol Urodyn, 1996, 15: 310-311.
  • 3[3]Nilvebrant L, Hallen B, Larsson G. Tolterodine-a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data [J]. Life Sci, 1997, 60:1129-36.
  • 4[4]Yono M, Yoshida M, Wada Y. Pharmacological effects of tolterodine on human isolated urinary bladder [J]. Eur J Pharmacol, 1999 , 368(2-3): 223-230.
  • 5[5]Stahl MMS, Ekstrom B, Sparf B, et al. Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity [J]. Neurourol Urodyn,1995, 14(6): 647-655.
  • 6[6]Gozzi P, Pahlman I. Serum protein binding of tolterodine and its 5-hydroxymethyl metabolite in different species[C].6th ISSX, 1997, Jun 30: 227.
  • 7[7]Postlind H,Danielson A, Lindgren A, et al. Tolterodine, a novel muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A4 in human liver microsomes[J]. Drug Metab Dispos, 1998, 26(4): 289-93.
  • 8[8]Brynne N, Aperia B, Aberg-Wistedt A, et al. Inhibition of tolterodine metabolism by fluoxetine with minor change in antimuscarinic activity [J]. Eur J Clin Pharmacol, 1997, 52Suppl: Al30.
  • 9[9]Chancellor M, Freedaman S, Mitcheson HD. Tolterodine,an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms[J]. Clin Drug Inuest, 2000, 19(2): 83-91.
  • 10[10]Messelink EJ. Treatment of the overactive bladder with tolterodine, a new muscarinic receptor antagonist[J]. BJU International, 1999, 83 Suppl 2: 48-52.

共引文献120

同被引文献25

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部